小林和史

研究者氏名	小林和史
	コバヤシカズフミ
URL
所属	千葉大学
部署	大学院医学研究院　消化器内科学
職名
学位	医学博士(千葉大学)
科研費研究者番号	40836615
J-Global ID	202101015962864350

論文

<2 345 6 >

Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus.

Yaojia Ma Shingo Nakamoto Junjie Ao Na Qiang Tadayoshi Kogure Keita Ogawa Miyuki Nakagawa Kisako Fujiwara Terunao Iwanaga Ryuta Kojima Hiroaki Kanzaki Keisuke Koroki Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Masato Nakamura Takayuki Kondo Ryo Nakagawa Sadahisa Ogasawara Ryosuke Muroyama Tetsuhiro Chiba Jun Kato Naoya Kato

International journal of molecular sciences 23(19) 2022年10月

A functional cure of hepatitis B virus (HBV) infection or HB antigen loss is rarely achieved by nucleos(t)ide analogs which target viral polymerase. HBx protein is a regulatory protein associated with HBV replication. We thought to identify antivi...

脈管侵襲を伴う進行肝細胞癌における薬物療法と適切な治療効果判定の検討

井上将法小笠原定久石野貴雅小川慶太岩永光巨宇野澤秀美弓田冴中川美由貴藤原希彩子神崎洋彰興梠慧輔小林和史中村昌人清野宗一郎叶川直哉近藤孝行中川良中本晋吾室山良介千葉哲博加藤順加藤直也

肝臓 63(Suppl.3) A780-A780 2022年10月

免疫チェックポイント阻害剤と抗VEGF抗体薬の併用療法によるネフローゼ症候群の治療に難渋した進行肝細胞癌の1例

赤塚鉄平神崎洋彰中川美由貴藤原希彩子岩永光巨兒島隆太興梠慧輔井上将法小林和史叶川直哉清野宗一郎中村昌人近藤孝行中川良小笠原定久中本晋吾室山良介千葉哲博加藤順加藤直也

日本消化器病学会関東支部例会プログラム・抄録集 371回 30-30 2022年9月

Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma.

Naoto Fujita Naoya Kanogawa Hirokazu Makishima Sadahisa Ogasawara Susumu Maruta Yotaro Iino Yuki Shiko Hiroaki Kanzaki Keisuke Koroki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Takayuki Kondo Shingo Nakamoto Tetsuhiro Chiba Masaru Wakatsuki Ei Itobayashi Masamichi Obu Yoshihiro Koma Ryosaku Azemoto Yohei Kawasaki Jun Kato Hiroshi Tsuji Naoya Kato

Hepatology research : the official journal of the Japan Society of Hepatology 52(12) 1060-1071 2022年8月

AIM: Carbon-ion radiotherapy (C-ion RT) has shown potential as a curative treatment for patients with hepatocellular carcinoma (HCC). However, no reports have compared the effectiveness of C-ion RT and radiofrequency ablation (RFA). This study aim...

Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old.

Rui Sato Michihisa Moriguchi Kenji Iwai Satoshi Tsuchiya Yuya Seko Aya Takahashi Kazufumi Kobayashi Sadahisa Ogasawara Shunji Watanabe Naoki Morimoto Naoya Kato Yoshito Itoh Takeshi Aramaki

Hepatology research : the official journal of the Japan Society of Hepatology 52(10) 859-871 2022年8月

AIM: There is insufficient evidence regarding the safety and efficacy of molecular targeted agents (MTAs) for elderly patients with hepatocellular carcinoma (HCC), who are likely to be vulnerable to adverse events (AEs) of therapy. The aim of this...